Treatment for 56 cases of recurrent oral ulcer associated with helicobacter pylori based on riple therapy

Abstract

Abstract:

AIM: To study the treatment for 56 cases recurrent oral ulcer (ROU) associated with helicobacter pylori (HP) based on the triple therapy so as to provide a new reference and idea for prevention and treatment of ROU patients in hope of improving the clinical curative effect. METHODS: One-hundred cases of ROU associated with HP were selected and randomly divided into observation group (56 cases) and control group (44 cases). The observation group was administered with the triple therapy combined with Kangfuxin liquid. While the control group was given single Kangfuxin liquid. Both groups received 7 d continuous treatment. The clinical curative effect, pain index, HS-CRP, ulcer healing time, adverse drug reaction, recurrence rate and eradication rate of HP within six months of two groups were compared. RESULTS: At the end of treatment, the cure rate of the observation group was 91.07% and total effective rate was 100%, and those of the control group were 65.91% and 86.36%, respectively. The differences were statistically significant (P<0.01). Compared with before treatment, pain index and HS-CRP of the two groups showed significant difference after treatment (P<0.01); and the observation group showed more significant difference than that of control group (P<0.05 or 0.01). Compared with the control group, ulcer surface healing time of the observation group showed significant difference (P<0.05). The two groups presented no drug-related death. And liver and kidney function were tested normal. The main adverse reactions were slightly dry mouth, nausea and poor appetite which showed no statistically significant difference (P>0.05), and patients tolerated the reaction without drug withdrawal. Comparison of eradication rate of HP and recurrence rate within six months was statistically significant (P<0.01). CONCLUSION: ROU is associated with HP; Kangfuxin liquid combined with the triple therapy to treat HP associated with ROU are effective, which can improve the symptoms and the HP removing rate, and reduce recurrence rate with no adverse reaction. It is referential for clinical application.

Key words: triple therapy, helicobacter pylori, recurrent oral ulcer, Kangfuxin liquid, clinical observation

CLC Number:

R781.5

FAN Meijun, WANG Jinling, MA Kai, KONG Xiuling. Treatment for 56 cases of recurrent oral ulcer associated with helicobacter pylori based on riple therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1050-1055.

References

［1］李冬梅，刘寨华，李同达，等. 许彭龄从脾胃论治复发性口腔溃疡经验［J］. 中国中医基础医学杂志，2012，18（7）：747-749.
［2］刘家明. 中西医结合治疗复发性口腔溃疡［J］. 长春中医药大学学报，2016，32（1）：181-182.
［3］张优琴，江春霞，王智巍，等. 复发性口腔溃疡的临床治疗进展［J］. 中国药房，2015，26（35）：5030-5032.
［4］Natah SS, Konttinen YT, Enattah NS, et al. Recurrent aphthous ulcers today: a review of the growing knowledge［J］. Int J Oral Max Surg，2004，33（3）：221.
［5］Riggio MP, Lennon A, Wray D. Detection of Helicobacter pylori DNA in recurrent aphthous stomatitis tissue by PCR ［J］. J Oral Pathol Med，2000，29（10）：507-513.
［6］Richter J, Grimmova M, Stiborova I, et al. Detection of Helicobacter pylori in the saliva of patients with recurrent aphthous stomatitis［J］. Cas Lek Cesk，2003，142（11）：665-669.
［7］邹林焘，胡运莲. 幽门螺杆菌与复发性口腔溃疡相关性的Meta分析［J］. 感染·炎症·修复，2013，14（2）：102-106.
［8］Karaca S, Seyhan M, Senol M, et al. The effect of gastric Helicobacter pylori eradication on recurrent aphthous stomatitis［J］. Int J Dermatol，2008，47（6）：615-617.
［9］唐金菊，杨永进，李广. 三种抗幽门螺杆菌法治疗复发性口腔溃疡的疗效观察［J］. 中国临床医师杂志（电子版），2014，8（12）：2260-2263.
［10］李秉琦. 口腔黏膜病学［M］. 第2版. 北京：人民卫生出版社，2003：49-56.
［11］孙传兴. 临床疾病诊断依据治愈好转标准［M］. 第2版. 北京：人民军医出版社，2002：639.
［12］宁小宁. 复发性口腔溃疡治疗及病因分析［J］. 中国现代药物应用，2013，7（9）：26-27.
［13］张贤梅，孙勤国. 复发性口腔溃疡发病机制及中西医结合治疗进展［J］. 时珍国医国药，2013，24（10）：2495-2497.
［14］Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis ［J］. Lancet，1983，1（8336）：1273-1275.
［15］ Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration ［J］. Lancet，1984，1（8390）：1311-1315.
［16］ Krajden S, Fuksa M, Anderson J, et al. Examination of human stomach biopsies, saliva, and dental plaque for Campylobacter pylori［J］. J Clin Microbiol，1989，27（6）：1397-1398.
［17］洪滔，李晓玲，高永博. 幽门螺杆菌感染与复发性口腔溃疡的相关性研究［J］. 中华医院感染学杂志，2014，24（6）：1440-1442.
［18］Long B, Chen K, Wu B, et al. Detection of Helicobacter pylori in oral cavity of patients with recurrent aphthous ulcer［J］. South Med Univ，2007，27（4）：477-478.
［19］金早蓉，宋斌，张国志，等. 幽门螺杆菌与口腔疾病研究新进展［J］.中国热带医学，2010，10（8）：1024-1026.
［20］刘胜. 复发性口腔溃疡药物治疗现状［J］. 天津药学，2012，24（3）：68-70.
［21］王琳瑛. 康复新液与口炎清治疗复发性口腔溃疡的疗效对比［J］. 中国药业，2014，23（8）：79-80.
［22］郭永谊，林子玲，黄瑞华. 康复新液治疗复发性口腔溃疡疗效分析［J］. 中国医药指南，2011，9（20）：198-199.
［23］陈东，黄英. 复发性口腔溃疡和幽门螺杆菌的相关性分析［J］. 实用医学杂志，2003，19（6）：615-616.
［24］谢东亮. 兰索拉唑三联疗法治疗上消化道溃疡的疗效［J］. 实用临床医学，2012，13（3）：26.
［25］陈骏. 三联疗法治疗78例复发性口腔溃疡的疗效分析［J］. 海峡药学，2013，25（6）：200-201.
［26］郑敏. 幽门螺杆菌所致复发性口腔溃疡与消化道溃疡相关性研究［J］. 西部中医药，2013，26（9）：135-136.

[1]	HUA Zhihui, LIU Dong, ZHANG Jiandong, CAI Siyu, GE Chunli, CHEN Nan, QI Qi. Clinical evaluation of the efficacy against helicobacter pylori by amoxicillin from volume-based procurement and potassium amoxicillin clavulanate [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1061-1066.
[2]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[3]	XIE Fangying, CHEN Zheli, GAO Yuelan. Effects of Yiqi Yangyinshengji recipe on rats with recurrent oral ulcer and its effect on mucosal inflammatory factors and immune function [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 20-26.
[4]	LI Jingjing, YU Yanxia, TANG Lian, ZHANG Jinkun, YU Qiang, SHANG Erning. Influence of clinical pharmaceutical care on medication compliance and treatment effect in Helicobacter pylori positive peptic ulcer outpatients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 199-204.
[5]	XIE Xiang-zhi, XU Guo-lei, WU Xin-fang, CHEN Jun. Clinical observation of stable angina pectoris with the treatment of Wumei Wan [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 83-85.
[6]	LI Juan, SHAO Hui, ZHONG Zheng-ling, CHU Ji-ru, XIE Hai-tang. Research advancement of heartleaf houttuynia herb on antibacterial action [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(12): 1427-1432.
[7]	PENG Xuan-jie. Efficacy of rabeprazole-based triple therapy in treatment of helicobacter pylori positive patient with portal hypertension gastric disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(12): 1416-1419.
[8]	LI Zhao-xu, ZHANG Jin-nan, REN Shuang, GAO Cheng-ying, SUN Yi, WANG Xue. Progress of clinical pharmacological study on rifabutin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(1): 1-9.
[9]	XING Ji-Ping, BAO Ju-Tai, LI Zhi-Tian, SUN Guo, ZHANG Rui-Hong, WANG Shuang-Min. Clinical evaluation of antitoxin cachet for coxsackie B myocarditis in treatment ofPatients with viral myocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(6): 701-703.
[10]	ZHU Hong-Feng, CHU Zheng-Fang, LIU Qin, HE Li-Zhang. Efficacy of combination of clarithromycin, colloidal bismuth subcitrate and metronidazole in short-term treatment of helicobacter pylori infection with recurrent abdominal in children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(6): 532-533.